menu
    • menu
    [{"orgOrder":0,"company":"Adcytherix","sponsor":"Pontifax","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Adcytherix","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Adcytherix \/ Pontifax","highestDevelopmentStatusID":"2","companyTruncated":"Adcytherix \/ Pontifax"},{"orgOrder":0,"company":"Adcytherix","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Series A Financing","leadProduct":"ADCX-020","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Adcytherix","amount2":0.12,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Adcytherix \/ Bpifrance","highestDevelopmentStatusID":"6","companyTruncated":"Adcytherix \/ Bpifrance"},{"orgOrder":0,"company":"Adcytherix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"ADCX-020","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Adcytherix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adcytherix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Adcytherix \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Adcytherix

    Menu

    Adcytherix

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Adcytherix

                            France arrow
                            Global ChemShow
                            Not Confirmed

                            Adcytherix

                            France arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADCX-020

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers

                            Details : ADCX-020 is an antibody-drug conjugate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            November 20, 2025

                            Lead Product(s) : ADCX-020

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Adcytherix

                            France arrow
                            Global ChemShow
                            Not Confirmed

                            Adcytherix

                            France arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADCX-020

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Bpifrance

                            Deal Size : $122.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Adcytherix Raises EUR 105M to Accelerate Antibody-Drug Conjugate Pipeline

                            Details : The Series A financing for ADCX-020, an unconjugated antibody targeting undisclosed cancer, aims to advance cancer therapeutics.

                            Product Name : ADCX-020

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            October 16, 2025

                            Lead Product(s) : ADCX-020

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Bpifrance

                            Deal Size : $122.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Adcytherix

                            France arrow
                            Global ChemShow
                            Not Confirmed

                            Adcytherix

                            France arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Pontifax

                            Deal Size : $32.2 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Adcytherix Launches with €30 Million in Seed Funding for Antibody Drug Conjugates

                            Details : The financing aims to fund Adcytherix to develop next-generation antibody-drug conjugates for the treatment of patients suffering from high unmet-need diseases such as neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 11, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Pontifax

                            Deal Size : $32.2 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth